Orelabrutinib,Rituximab and Methotrexate in Newly-diagnosed Primary Central Nervous System Lymphoma(PCNSL)
Condition(s):Primary Central Nervous System LymphomaLast Updated:September 22, 2022Recruiting
Hide Studies Not Open or Pending
Condition(s):Primary Central Nervous System LymphomaLast Updated:September 22, 2022Recruiting
Condition(s):T-LGL Leukemia; Clpd-NkLast Updated:July 1, 2020Recruiting
Condition(s):Low Dose Methotrexate in Severe Chronic AsthmaLast Updated:September 28, 2021Unknown status
Condition(s):Ectopic PregnancyLast Updated:March 8, 2024Not yet recruiting
Condition(s):Lymphoma, T-Cell, Cutaneous; Mycosis FungoidesLast Updated:January 13, 2022Terminated
Condition(s):SchizophreniaLast Updated:December 12, 2017Unknown status
Condition(s):Crohn’s DiseaseLast Updated:December 11, 2013Completed
Condition(s):Chronic UrticariaLast Updated:September 20, 2017Completed
Condition(s):Atherosclerosis; Coronary Artery Disease; InflammationLast Updated:November 10, 2020Unknown status
Condition(s):WartsLast Updated:March 29, 2022Unknown status
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.